Search clinical trials for: Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2

Total 505 results

City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children

Malignant Brain Neoplasm | Recurrent Malignant Brain Neoplasm | Refractory Malignant Brain Neoplasm

United States
M.D. Anderson Cancer Center
Ziopharm Oncology

Terminated

CD19-Specific T Cells Post AlloSCT

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory B Acute Lymphoblastic Leukemia | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Juno Therapeutics, Inc.

Completed

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Jonsson Comprehensive Cancer Center

Recruiting

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Progressive Disease | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular... and other conditions

United States
Inge Marie Svane

Completed

Vemurafenib and TIL Therapy for Metastatic Melanoma

Metastatic Melanoma

Denmark
The Cleveland Clinic
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients With Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Breast Neoplasms

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Breast Neoplasms

China
Immatics US, Inc.
M.D. Anderson Cancer Center

Completed

ACTolog in Patients With Solid Cancers (ACTolog)

Cancer | Solid Tumor

United States
Yale University

Terminated

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

Metastatic Melanoma

United States
First Affiliated Hospital of Guangxi Medical University

Unknown

Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism

Beta Thalassemia Major

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma

Melanoma (Skin)

United States
Beijing YouAn Hospital

Unknown

Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC

Hepatocellular Carcinoma

China
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Small Intestine Cancer | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Precancerous/Nonmalignant Condition

United States
Western Regional Medical Center

Withdrawn

Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma

Metastatic Melanoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies

Hematopoietic and Lymphoid Cell Neoplasm

United States
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy

Recruiting

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | CD20 Positive | Refractory Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Refractory... and other conditions

United States
University of Colorado, Denver
National Cancer Institute (NCI)

Completed

Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors

Brain and Central Nervous System Tumors

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

Cervical Cancer | Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer

United States
Mayo Clinic

Recruiting

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission

B Acute Lymphoblastic Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

Platinum-Resistant Ovarian Carcinoma

United States
Fred Hutchinson Cancer Center
Mustang Bio

Active, not recruiting

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditions

United States
University of Rochester

Completed

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

Kidney Cancer

United States
National Cancer Institute (NCI)

Completed

Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent... and other conditions

United States
Leiden University
Bristol-Myers Squibb

Active, not recruiting

TIL and Anti-PD1 in Metastatic Melanoma (ACTME)

Effects of Immunotherapy | Adverse Drug Event | Toxicity, Drug

Netherlands
Meyer Pharmaceuticals

Unknown

Chemotherapy Compared to Biological Therapy in Treating Patients With Cancer of the Pancreas

Pancreatic Cancer

United States
Sumithira Vasu
National Cancer Institute (NCI)

Recruiting

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditions

United States
Genta Incorporated

Completed

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Leukemia

United States
M.D. Anderson Cancer Center
KSQ Therapeutics, Inc.

Recruiting

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Melanoma | Head and Neck Neoplasms | Lung Neoplasms | Advanced Solid Tumor

United States
Genocea Biosciences, Inc.

Terminated

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Melanoma | Renal Cell Carcinoma | Squamous Cell Carcinoma of Head and Neck | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Urothelial Carcinoma | Anal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Baylor College of Medicine

Completed

Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation

Kidney Cancer

United States
Karolinska University Hospital

Recruiting

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Melanoma

Sweden
Inge Marie Svane

Completed

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

Metastatic Ovarian Cancer

Denmark
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Ziopharm Oncology

Completed

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Minimal Residual Disease | Small Lymphocytic Lymphoma | Acute Biphenotypic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia | CD19 Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells

United States
Herlev Hospital

Completed

Dendritic Cell Based Therapy of Malignant Melanoma

Advanced Melanoma

Denmark
Celyad Oncology SA
IQVIA Biotech

Completed

DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 (DEPLETHINK)

AML | MDS

United States, Belgium
Crystal Mackall, MD

Recruiting

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Refractory Acute Lymphoblastic Leukemia | Minimal Residual Disease | CD19 Positive

United States
Crystal Mackall, MD
California Institute for Regenerative Medicine (CIRM)

Active, not recruiting

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Minimal Residual Disease | CD19 Positive

United States
Leiden University Medical Center

Recruiting

Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer (OVACURE)

Ovarian Cancer Recurrent

Netherlands
M.D. Anderson Cancer Center

Terminated

Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma

Neuroblastoma

United States
UNICANCER

Completed

Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer

France
National Cancer Institute (NCI)

Completed

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

Melanoma | Malignant Melanoma | Melanoma, Experimental | Experimental Melanomas

United States
University of Southern California
National Cancer Institute (NCI)

Not yet recruiting

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Withdrawn

Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma

Lymphoma

United States

Search clinical trials for: Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations